Neonatal abstinence syndrome: Pharmacologic strategies for the mother and infant

Area of Science:

• Obstetrics and Gynecology
• Neonatology
• Pharmacology

Background:

• Opioid use in pregnancy has significantly increased, posing a major public health concern.
• Prenatal opioid exposure is linked to severe obstetrical and neonatal complications, including neonatal abstinence syndrome (NAS).
• NAS is characterized by central nervous system hyperirritability and autonomic dysfunction in newborns.

Purpose of the Study:

• To review current clinical practices for managing pregnant individuals with opioid dependence and their neonates exposed in utero.
• To discuss the established and emerging therapeutic strategies for opioid-dependent pregnancies and NAS.
• To explore the role of genetic factors in NAS development and the potential for personalized medicine.

Main Methods:

• This is a review article, synthesizing current literature and clinical guidelines.
• It examines pharmacologic and non-pharmacologic approaches to prenatal opioid exposure.
• It discusses the diagnosis and management of neonatal abstinence syndrome (NAS).

Main Results:

• Opioid maintenance therapy is the cornerstone of prenatal management for opioid dependence, though the optimal agent remains undetermined.
• Pharmacologic management of NAS is highly variable, with options including opioids, barbiturates, and alpha-agonists.
• Genetic factors are associated with NAS incidence and severity, suggesting a role for pharmacogenetics.

Conclusions:

• Effective management of prenatal opioid exposure requires a comprehensive approach to both mother and neonate.
• Further research is needed to establish optimal pharmacologic agents for opioid maintenance and NAS treatment.
• Identifying pharmacogenetic risk factors could enable personalized genomic medicine for individualized NAS interventions.